GlassScriptPhysician profile
Bailee Blackburn
NPI 1992246177
$6,666.05
in general payments reported to CMS, 2019-2025
29 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.78 · 2020: $510 · 2021: $842 · 2022: $695 · 2023: $1,448 · 2024: $1,887 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,485 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,484.92 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,119.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $907.91 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $746.90 | 2020-2025 | Vraylar, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $716.29 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $686.94 | 2021-2025 | |
| Amarin Pharma, INC. | $347.72 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.89 | 2020-2025 | Jardiance, Ofev |
| Astellas Pharma US INC | $282.40 | 2021-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $256.31 | 2020-2025 | |
| Amgen INC. | $159.54 | 2022-2025 | Repatha, Otezla, Tepezza |
| Sanofi-Aventis U.S. LLC | $149.20 | 2024-2025 | |
| Exact Sciences Corporation | $130.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $127.40 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lucid Diagnostics INC. | $97.19 | 2023 | |
| Esperion Therapeutics, INC. | $79.80 | 2020-2023 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $72.26 | 2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.63 | 2021-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $57.63 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $51.68 | 2024 | Rexulti |
| Allergan, INC. | $46.08 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.00 | 2022 | |
| Sumitomo Pharma America, INC. | $34.49 | 2025 | Gemtesa |
| Supernus Pharmaceuticals, INC. | $31.78 | 2024-2025 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $25.77 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $23.70 | 2025 | Keveyis |
| Ultragenyx Pharmaceutical INC. | $21.41 | 2021 | |
| Vivus LLC | $20.91 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.01 | 2025 | Caplyta |
| Metacel Pharmaceuticals LLC | $13.50 | 2025 | Ozobax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bailee Blackburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.